BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:40 PM
 | 
Jan 18, 2019
 |  BC Week In Review  |  Company News  |  Deals

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets.

MD Anderson's collaboration with Nanobiotix will initially focus on nine Phase I/II clinical trials of NBTXR3 (PEP503) across different radiation modalities for head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers....

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >